Encyclopedia of Heart Diseases

2011 Edition
| Editors: M. Gabriel Khan

Aspirin for Heart Disease

Reference work entry
DOI: https://doi.org/10.1007/978-1-60761-219-3_20

Overview

One does not have to believe in Adam and Eve to recognize the significance of an apple. The old saying “an apple a day keeps the doctor away” has been changed to “an aspirin a day keeps the doctor away” (Fig. 1). Worldwide, aspirin is the most used drug. The following pointers indicate why aspirin usage has increased:
This is a preview of subscription content, log in to check access.

Bibliography

References

  1. Cairns JA, Gent M, Singer J et al (1986) Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 313:1369Google Scholar
  2. Elwood PC, Cochrane AL, Burr ML et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1:436–440PubMedGoogle Scholar
  3. Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51:1829–1843PubMedGoogle Scholar
  4. Juul-Moller S, Edvardsson N, Jhnmatz B et al (1992a) Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 340:1421PubMedGoogle Scholar
  5. Kapoor JR (2008) Enteric coating is a possible cause of aspirin resistance. J Am Coll Cardiol 52:1276–1277PubMedGoogle Scholar
  6. Maree AO, Curtin RJ, Dooley M et al (2005) Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46:1258–1263PubMedGoogle Scholar
  7. Marson P, Pasero G (2006) The Italian contributions to the history of salicylates. Reumatismo 58:66–75PubMedGoogle Scholar
  8. Nissen SE (2009) The vulnerable plaque “hypothesis”: promise, but little progress. J Am Coll Cardiol Imaging 2(4):483–485Google Scholar
  9. Resnekov L, Chekiak J, Hirsh J et al (1989) Antithrombotic agents in coronary artery disease. Chest 95:528Google Scholar
  10. Ridker PM, Cook NR, Lee IM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304PubMedGoogle Scholar
  11. Vainio H, Morgan G (1997) Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol 81:151–152PubMedGoogle Scholar

Suggested Reading

  1. Craven LL (1953) Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Val Med J 75:38Google Scholar
  2. Lewis HD, Davis JW, Archibald DG et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396PubMedGoogle Scholar
  3. Vane JN (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235PubMedGoogle Scholar

Case Studies

  1. Aronow HD, Califf RM, Harrington RA et al BRAVO Trial Investigators (2008) Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol 102:1285–1290Google Scholar
  2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 11:349–350. ISIS-2Google Scholar
  3. Juul-Moller S, Edvardsson N, Jhnmatz B et al (1992b) Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 340:1421. The Swedish Angina Pectoris Aspirin TrialPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2011